Literature DB >> 833343

The effect of quinidine sulfate on QRS duration and QT and systolic time intervals in man.

A Fieldman, R D Beebe, M Sing Sum Chow.   

Abstract

QRS duration, QT interval, total electromechanical systole (QS(2)), left ventricular ejection time (LVET), and preejection period (PEP) were determined in five male and two female healthy volunteers in a fasting state at hourly intervals for 7 hours during a control period and after administration of 400 mg quinidine sulfate. Changes of QRS duration (delta QRS) and rate-corrected QT interval (delta QTc) were calculated before and after quinidine. Deviations of measured QS(2), LVET, and PEP from the normal were calculated as the differences between the observed interval and those predicted from the normal regression equation. The effect of quinidine on systolic time intervals (delta QS(2), delta LVET, DELTA PEP) were expressed as the differences between the deviations from the normal regression equation during the control period and after the drug administration. After quinidine sulfate delta QRS, delta LVET, delta PEP, and delta PEP, delta LVET were slight and inconsistent. However, delta QTc and delta QS(2) were significant (at P is less than 0.05 or better) from the first hour to the 7th hour and from the 2nd hour to the 5th hour, respectively. The mean maximum delta QTc was 44.8 milliseconds and delta QS(2) was 29.9 milliseconds. The significant changes of QTc and QS(2) seemed to occur at the plasma level range of 0.75-1.9 mug/ml. This study indicates that of the various systolic time interval measurements obtained after quinidine administration, the changes of QT interval and QS(2) are most significant and that these changes seem to occur even at low plasma levels.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 833343     DOI: 10.1002/j.1552-4604.1977.tb04600.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

Review 1.  Systolic time intervals in clinical pharmacology.

Authors:  Q Li; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Pharmacodynamics of a single dose of quinidine during chronic digoxin treatment. A randomized double blind placebo and sparteine--controlled crossover study.

Authors:  G G Belz; P E Aust; W Doering; M Heinz; B Schneider
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

4.  Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.

Authors:  J M St-Onge; G Sirois; M A Gagnon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.